JPRN-UMIN000019192已完成未知
Investigation of the Effect of Dapagliflozin on Body Composition and Diet in Japanese Patients with Type 2 Diabetes Mellitus - Dapagliflozin Intervention Trial (DIET)
Department of Medicine and Bioregulatory, Graduate School of Medical Sciences, Kyushu University0 个研究点目标入组 60 人开始时间: 2015年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
As a result of treatment with dapagliflozin to 54 Japanese patients with type 2 diabetes for 2 years, body weight was significantly reduced, in addition to the improvement of blood glucose and blood pressure. This study suggested that most of the weight loss was due to the decreases in body fat mass and fatty liver.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with type 1 diabetes mellitus or secondary diabetes. 2) Patients with infection, postoperative/preoperative status, or severe trauma. 3) Patients with a history of myocardial infarction, angina pectoris, stroke, cerebral infarction, or transient ischemic attacks (TIA). 4) Patients with diabetic retinopathy requiring photocoagulation or vitreous surgery or those who have undergone any of these operations within one year. 5) Patients with moderate or worse renal dysfunction (eGFR < 45mL/min/1.73m2). 6) Patients with severe hepatic dysfunction (Child-Pugh Class C) or liver cirrhosis. 7) Patients with moderate or severe cardiac failure (New York Heart Association Class III or IV). 8) Patients taking GLP-1 receptor agonists. 9) Pregnant or breast-feeding women, as well as women of childbearing potential or those who plan to become pregnant. 10) Patients with a history of hypersensitivity to the study drug. 11) Patients with severe ketosis, diabetic coma, or precoma. 12) Patients with pacemaker. 13) Other patients who are deemed to be inappropriate for the study by the attending physician.
研究者
相似试验
已完成
不适用
The Japanese T2D study for evaluating Benefits Of a New first-line therapy with Dapagliflozin in consideration of improving QOD003924Type 2 Diabetes MellitusDiabetes Mellitus, Type 2JPRN-jRCTs051180165Ishii Hitoshi253
已完成
不适用
Effect of Dapagliflozin in patients with type 2 daibetes mellitusType 2 diabetes mellitusJPRN-UMIN000014922Iwasaki Naika Clinic50
尚未招募
不适用
Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liverJPRN-UMIN000026549Kagawa prefectural central hospital25
已完成
不适用
Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in TaiwanType II Diabetes MellitusNCT03084965AstraZeneca1,987
招募中
2 期
A single-site study of the effectiveness of Dapagliflozin for diabetic patients admitted to the intensive care unitMetabolic and Endocrine - DiabetesDiabetesACTRN12621001102864Austin Health40